Antineoplastic And Immunomodulating Agents – Medicinal Product For Autologous Cell Therapy - Brexukabtagen Autoleucel - 2025. The Subject Of The Public Contract Is The Supply Of A Medicinal Product Intended For The Therapy Of Malignant Blood Diseases In The Total Expected Volume Of 16 Individual Doses Of The Medicinal Product. The Preparation Is Intended For The Provision Of Health Care At The Medical Workplace Of The Fn Plzeň. Deliveries Of The Subject Of Performance Will Be Carried Out On The Basis Of The Results Of The Completed Procurement Procedure For A Period Of Four Years From The Signing Of The Purchase Contract. Cytostatic Agent For Car-T Therapy (Brexukabtagen Autoleucel) - Infusion Bag Containing A Cell Dispersion Of 0.4 - 2X10^8 Viable Anti-Cd19 Car-Positive T-Lymphocytes. The Expected Annual Volume Is 4 Infusion Bags Containing An Individually Determined Amount Of The Active Ingredient, Atc L01xl06.
We takes all possible care for accurate & authentic tender information, however Users are requested to refer Original source of Tender Notice / Tender Document published by Tender Issuing Agency before taking any call regarding this tender.
